EMA "Moderna Vaccine Evaluation Meeting Moved Up"

[Image source=Yonhap News]

[Asia Economy Reporter Yujin Cho] The European Medicines Agency (EMA) announced on the 17th (local time) that it will hold a meeting on the 6th of next month, about six days earlier than originally scheduled, to evaluate whether to approve the sale of the novel coronavirus disease (COVID-19) vaccine developed by the U.S. pharmaceutical company Moderna.

EMA stated that Moderna submitted the final data required for the evaluation of the approval application earlier than expected.

Moderna was the first among COVID-19 vaccines developed worldwide to enter clinical trials, and last month announced that the results of its Phase 3 clinical trial showed an efficacy of 94.1% for its vaccine.

Recently, EMA also moved up the meeting to decide on the approval of the COVID-19 vaccine jointly developed by the U.S. pharmaceutical company Pfizer and the German company BioNTech from the originally scheduled 29th to the 21st.

When EMA issues a recommendation on a new medicine, the European Commission, the EU's executive body, makes the final decision, usually following EMA's advice.

Once the EU Commission grants official approval, each member state can immediately begin vaccination.

[Image source=Yonhap News]

This content was produced with the assistance of AI translation services.